-
公开(公告)号：WO2012027328A2
公开(公告)日：2012-03-01
申请号：PCT/US2011048752
申请日：2011-08-23
Applicant: UNIV TEXAS , LIU YONG-JUN , VOO KUI SHIN , BOVER LAURA , TSURUSHITA NAOYA , TSO J YUN , KUMAR SHANKAR
Inventor： LIU YONG-JUN , VOO KUI SHIN , BOVER LAURA , TSURUSHITA NAOYA , TSO J YUN , KUMAR SHANKAR
IPC: C07K16/28 , A61K39/395 , A61P35/00 , C12N15/13
CPC classification number: C07K16/2878 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/74 , C07K2317/75
Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.
Abstract translation: 公开了与人OX40特异性结合的人抗体，优选重组人抗体，其是人源化的和嵌合的。 优选的抗体对OX40受体具有高亲和力并在体外和体内激活受体。 抗体可以是全长抗体或其抗原结合部分。 抗体或抗体部分可用于调节受体活性，例如在患有OX40活性有害的病症的人类受试者中。 还提供了用于表达重组人抗体的核酸，载体和宿主细胞，以及合成重组人抗体的方法。
-
公开(公告)号：WO2010065536A3
公开(公告)日：2010-06-10
申请号：PCT/US2009/066246
申请日：2009-12-01
Inventor： CAO, Wei , LIU, Yong-Jun
Abstract: Methods, compositions and kits are disclosed for inhibiting interferon production and modulating immune responses, particularly an autoimmune response. In certain embodiments, the methods involve administering an effective amount of a BST2 protein or a nucleic acid encoding an BST2 protein to treat an autoimmune disease or disorder.
-
3.发明申请RECOMBINANT BONE MARROW STROMAL ANTIGEN-2 IN THE TREATMENT OF AUTOIMMUNE DISEASES 审中-公开重组骨髓基质抗原2治疗自身免疫性疾病
公开(公告)号：WO2010065536A2
公开(公告)日：2010-06-10
申请号：PCT/US2009066246
申请日：2009-12-01
Applicant: UNIV TEXAS , CAO WEI , LIU YONG-JUN
Inventor： CAO WEI , LIU YONG-JUN
CPC classification number: A61K38/177 , C07K14/705 , C07K2319/30
Abstract: Methods, compositions and kits are disclosed for inhibiting interferon production and modulating immune responses, particularly an autoimmune response. In certain embodiments, the methods involve administering an effective amount of a BST2 protein or a nucleic acid encoding an BST2 protein to treat an autoimmune disease or disorder.
Abstract translation: 公开了用于抑制干扰素产生和调节免疫应答，特别是自身免疫应答的方法，组合物和试剂盒。 在某些实施方案中，所述方法包括施用有效量的BST2蛋白或编码BST2蛋白的核酸以治疗自身免疫疾病或病症。
-
4.发明申请METHODS TO TREAT DISEASE STATES BY INFLUENCING THE SIGNALING OF OX40-RECEPTORS AND HIGH THROUGHPUT SCREENING METHODS FOR IDENTIFYING SUBSTANCES THEREFOR 审中-公开通过影响OX40-受体的信号传导和高通量筛选方法来鉴定疾病的方法来治疗疾病状态
公开(公告)号：WO2007084559A3
公开(公告)日：2007-11-22
申请号：PCT/US2007001228
申请日：2007-01-16
Applicant: UNIV TEXAS , LIU YONG-JUN , ITO TOMOKI
Inventor： LIU YONG-JUN , ITO TOMOKI
IPC: C07K14/00 , A61K39/395
CPC classification number: A61K38/177 , C07K16/2878 , G01N33/505 , G01N33/56972 , G01N2333/5428
Abstract: OX40L inhibits the generation of IL-10-producing Tr1 cells from naïve and memory CD4+ T cells induced by the immunosuppressive drugs dexamethasone and vitamin D3. This unique function of OX40L is not shared by two other costimulatory TNF-family members, GITR-ligand and 4-1BB-ligand. OX40L also strongly inhibits the generation of IL-10-producing Tr1 cells induced by two physiological stimuli provided by inducible costimulatory ligand and immature DCs and inhibits the production of IL-10 by regulatory T cells. It has thus been shown that signaling the OX40-receptor on human T cells by monoclonal antibodies, small molecules, or OX40L regulates the generation and function of IL-10 producing immunosuppressive T cells. Also provided are high throughput methods for identifying substances that promote or inhibit the generation and function of IL-10 producing T cells. Numerous disease states, such as human allergic, autoimmune, and autoimmune diseases, and cancer, may be treated by targeting OX40/OX40L.
Abstract translation: OX40L抑制由免疫抑制药物地塞米松和维生素D3诱导的幼稚和记忆CD4 + T细胞产生IL-10的Tr1细胞。 OX40L的这种独特功能不被其他两种共刺激性TNF家族成员GITR配体和4-1BB配体共享。 OX40L还强烈抑制由诱导型共刺激配体和未成熟DC提供的两种生理刺激诱导的产生IL-10的Tr1细胞的生成，并抑制调节性T细胞产生IL-10。 因此已经表明，通过单克隆抗体，小分子或OX40L信号通知人T细胞上的OX40-受体调节产生免疫抑制性T细胞的IL-10的产生和功能。 还提供了用于鉴定促进或抑制产生IL-10的T细胞的产生和功能的物质的高通量方法。 可以通过靶向OX40 / OX40L来治疗许多疾病状态，例如人过敏性，自身免疫性和自身免疫性疾病以及癌症。
-
5.发明申请METHODS TO TREAT DISEASE STATES BY INFLUENCING THE SIGNALING OF OX40-RECEPTORS AND HIGH THROUGHPUT SCREENING METHODS FOR IDENTIFYING SUBSTANCES THEREFOR 审中-公开通过影响OX40受体信号和高通量筛选方法治疗疾病的方法，用于鉴定其物质
公开(公告)号：WO2007084559A2
公开(公告)日：2007-07-26
申请号：PCT/US2007/001228
申请日：2007-01-16
Inventor： LIU, Yong-Jun , ITO, Tomoki
IPC: A61K38/19
CPC classification number: A61K38/177 , C07K16/2878 , G01N33/505 , G01N33/56972 , G01N2333/5428
Abstract: OX40L inhibits the generation of IL-10-producing Tr1 cells from naïve and memory CD4+ T cells induced by the immunosuppressive drugs dexamethasone and vitamin D3. This unique function of OX40L is not shared by two other costimulatory TNF-family members, GITR-ligand and 4-1BB-ligand. OX40L also strongly inhibits the generation of IL-10-producing Tr1 cells induced by two physiological stimuli provided by inducible costimulatory ligand and immature DCs and inhibits the production of IL-10 by regulatory T cells. It has thus been shown that signaling the OX40-receptor on human T cells by monoclonal antibodies, small molecules, or OX40L regulates the generation and function of IL-10 producing immunosuppressive T cells. Also provided are high throughput methods for identifying substances that promote or inhibit the generation and function of IL-10 producing T cells. Numerous disease states, such as human allergic, autoimmune, and autoimmune diseases, and cancer, may be treated by targeting OX40/OX40L.
Abstract translation: OX40L抑制由免疫抑制药物地塞米松和维生素D3诱导的初始和记忆CD4 + T细胞产生产生IL-10的Tr1细胞。 OX40L的这种独特功能不是由另外两种共刺激的TNF-家族成员，GITR-配体和4-1BB-配体共享。 OX40L还强烈地抑制由诱导性共刺激配体和未成熟DC提供的两种生理刺激诱导的产生IL-10的Tr1细胞的产生，并通过调节性T细胞抑制IL-10的产生。 因此，已经表明，通过单克隆抗体，小分子或OX40L信号传导人T细胞上的OX40-受体调节产生IL-10的免疫抑制性T细胞的产生和功能。 还提供了用于鉴定促进或抑制产生IL-10和产生T细胞的功能的物质的高通量方法。 可以通过靶向OX40 / OX40L来治疗许多疾病状态，例如人类过敏，自身免疫和自身免疫疾病和癌症。
-
Patent Agency Ranking
公开(公告)号：WO2013028231A1
公开(公告)日：2013-02-28
申请号：PCT/US2012/024570
申请日：2012-02-09
Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , LIU, Yong-Jun , VOO, Kui Shin , BOVER, Laura , TSURUSHITA, Naoya , TSO, J. Yun , KUMAR, Shankar
Inventor： LIU, Yong-Jun , VOO, Kui Shin , BOVER, Laura , TSURUSHITA, Naoya , TSO, J. Yun , KUMAR, Shankar
IPC: C07K16/28 , C12N15/13 , C12N15/63 , A61K39/395 , A61P35/00
CPC classification number: C07K16/205 , A61K2039/505 , C07K16/2878 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/73 , C07K2317/74 , C07K2317/76 , C07K2317/92
Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full- length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.
Abstract translation: 公开了与人OX40特异性结合的人抗体，优选重组人抗体，人源化和嵌合。 优选的抗体对OX40受体具有高亲和力，并在体外和体内激活受体。 抗体可以是全长抗体或其抗原结合部分。 抗体或抗体部分可用于调节受体活性，例如在患有OX40活性有害的病症的人类受试者中。 提供用于表达重组人抗体的核酸，载体和宿主细胞，并提供合成重组人抗体的方法。
-
公开(公告)号：WO2012027328A3
公开(公告)日：2012-03-01
申请号：PCT/US2011/048752
申请日：2011-08-23
Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , LIU, Yong-Jun , VOO, Kui Shin , BOVER, Laura , TSURUSHITA, Naoya , TSO, J., Yun , KUMAR, Shankar
Inventor： LIU, Yong-Jun , VOO, Kui Shin , BOVER, Laura , TSURUSHITA, Naoya , TSO, J., Yun , KUMAR, Shankar
IPC: C07K16/28 , C12N15/13 , A61K39/395 , A61P35/00
Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.
-
8.发明申请
公开(公告)号：WO2008076981A2
公开(公告)日：2008-06-26
申请号：PCT/US2007/087787
申请日：2007-12-17
Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM , LANDE, Roberto , LIU, Yong-jun , GILLIET, Michel
Inventor： LANDE, Roberto , LIU, Yong-jun , GILLIET, Michel
IPC: A61K39/395
CPC classification number: C12N5/0639 , A61K39/00 , A61K39/39 , A61K2039/5152 , A61K2039/53 , A61K2039/55516 , A61K2039/55561 , C12N2501/24
Abstract: Methods and compositions for treating disease are provided. More particularly, methods and compositions of inhibiting pathogenic interferon production are prevented, which may be useful in the treatment of various diseases. In other embodiments, therapeutic compounds and methods for the treatment of autoimmune diseases and chronic inflammatory diseases are provided. One such method is a method for inhibiting pathogenic interferon production or inhibiting activation of plasmacytoid dendritic cells or treating an autoimmune or chronic inflammatory disease, which comprises inhibiting one or more of LL-37 and hCAP18.
Abstract translation: 提供了用于治疗疾病的方法和组合物。 更具体地说，阻止了致病性干扰素产生的方法和组合物，其可用于治疗各种疾病。 在其他实施方案中，提供了用于治疗自身免疫疾病和慢性炎症疾病的治疗化合物和方法。 一种这样的方法是抑制致病性干扰素产生或抑制浆细胞样树突状细胞活化或治疗自身免疫性或慢性炎性疾病的方法，其包括抑制LL-37和hCAP18中的一种或多种。
-
9.发明申请AGONISTS OR ANTAGONISTS OF THE CLUCOCORTICOID-INDUCED TUMOUR NECROSIS FACTOR RECEPTOR (GITR) OR ITS LIGAND FOR THE TREATMENT OF IMMUNE DISORDERS, INFECTIONS AND CANCER 审中-公开CLOCOCORTICOID诱导的肿瘤坏死因子受体（GITR）或其配体治疗免疫缺陷病毒，感染和癌症的激素或拮抗剂
公开(公告)号：WO2005007190A1
公开(公告)日：2005-01-27
申请号：PCT/US2004/021769
申请日：2004-07-08
Applicant: SCHERING CORPORATION , HANABUCHI, Shino , DE WAAL MALEFYT, Rene , LIU, Yong-Jun
Inventor： HANABUCHI, Shino , DE WAAL MALEFYT, Rene , LIU, Yong-Jun
IPC: A61K39/395
CPC classification number: C07K16/24 , C07K16/2866 , C07K2317/74
Abstract: Provided are methods of modulating activity of regulatory T cells, CD4 + T cells, and CD8 + T cells. Also provided are methods of treating immune disorders, infections and cancer. To this end agonists or antagonists of the glucocorticoid-induced tumor necrosis factor receptor (GITR) or its ligand are used.
Abstract translation: 提供调节T细胞，CD4 + T细胞和CD8 + T细胞活性的方法。 还提供了治疗免疫疾病，感染和癌症的方法。 为此，使用糖皮质激素诱导的肿瘤坏死因子受体（GITR）或其配体的激动剂或拮抗剂。
-
10.发明申请
公开(公告)号：WO2008076981A3
公开(公告)日：2008-10-23
申请号：PCT/US2007087787
申请日：2007-12-17
Applicant: UNIV TEXAS , LANDE ROBERTO , LIU YONG-JUN , GILLIET MICHEL
Inventor： LANDE ROBERTO , LIU YONG-JUN , GILLIET MICHEL
CPC classification number: C12N5/0639 , A61K39/00 , A61K39/39 , A61K2039/5152 , A61K2039/53 , A61K2039/55516 , A61K2039/55561 , C12N2501/24
Abstract: Methods and compositions for treating disease are provided. More particularly, methods and compositions of inhibiting pathogenic interferon production are prevented, which may be useful in the treatment of various diseases. In other embodiments, therapeutic compounds and methods for the treatment of autoimmune diseases and chronic inflammatory diseases are provided. One such method is a method for inhibiting pathogenic interferon production or inhibiting activation of plasmacytoid dendritic cells or treating an autoimmune or chronic inflammatory disease, which comprises inhibiting one or more of LL-37 and hCAP18.
Abstract translation: 提供了治疗疾病的方法和组合物。 更具体地，可以预防抑制致病性干扰素产生的方法和组合物，其可用于治疗各种疾病。 在其它实施方案中，提供了用于治疗自身免疫疾病和慢性炎性疾病的治疗化合物和方法。 一种这样的方法是抑制致病性干扰素产生或抑制浆细胞样树突状细胞活化或治疗自身免疫性或慢性炎性疾病的方法，其包括抑制LL-37和hCAP18中的一种或多种。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.014 seconds)
